da Silva Jorge Santos
CIK: 0001920509
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
MoonLake Immunotherapeutics
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jul 10, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct68.3K shares at avg. $20.02$1.4M - Jul 9, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct33.9K shares at avg. $20.01$679K - Jul 1, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct47.8K shares at avg. $20.03$957K - Apr 13, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct51.9K shares at avg. $18.23$946K - Apr 10, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Direct98.1K shares at avg. $18.41$1.8M - Jan 7, 2026MLTX
MoonLake Immunotherapeutics
Award(A)DirectStock Option (Right to Buy)
520.3K shares- - Dec 19, 2025MLTX
MoonLake Immunotherapeutics
Disposition(D)Direct196.3K shares- - Dec 19, 2025MLTX
MoonLake Immunotherapeutics
Conversion(C)Direct196.3K shares- - Dec 9, 2025MLTX
MoonLake Immunotherapeutics
Sale(S)Direct70K shares at avg. $14.49$1.0M - Dec 8, 2025MLTX
MoonLake Immunotherapeutics
Sale(S)Direct130K shares at avg. $15.08$2.0M - Feb 27, 2025MLTX
MoonLake Immunotherapeutics
Award(A)Direct95.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 10, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 68,289 | $20.02 | $1,367,146 | Direct |
| Jul 9, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 33,936 | $20.01 | $679,059 | Direct |
| Jul 1, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 47,775 | $20.03 | $956,933 | Direct |
| Apr 13, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 51,873 | $18.23 | $945,645 | Direct |
| Apr 10, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 98,127 | $18.41 | $1,806,518 | Direct |
| Jan 7, 2026 | MLTX MoonLake Immunotherapeutics | Award(A) Stock Option (Right to Buy) | 520,342 | - | - | Direct |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | Disposition(D) | 196,316 | - | - | Direct |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | Conversion(C) | 196,316 | - | - | Direct |
| Dec 9, 2025 | MLTX MoonLake Immunotherapeutics | Sale(S) | 70,000 | $14.49 | $1,014,300 | Direct |
| Dec 8, 2025 | MLTX MoonLake Immunotherapeutics | Sale(S) | 130,000 | $15.08 | $1,960,400 | Direct |
| Feb 27, 2025 | MLTX MoonLake Immunotherapeutics | Award(A) | 95,763 | - | - | Direct |
1-11 of 11 transactions
About Santos da Silva Jorge
Santos da Silva Jorge (SEC CIK 0001920509) files insider reports with the SEC as Chief Executive Officer of MoonLake Immunotherapeutics (MLTX).
Signal8 holds 7 ownership filings by Santos da Silva Jorge, all Form 4s, filed between Mar 3, 2025 and Jul 13, 2026. Those filings report 11 transactions, from Feb 27, 2025 to Jul 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Santos da Silva Jorge's filings is in ZUG.
Recent filings by Santos da Silva Jorge
- Jul 10, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jul 9, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jul 1, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Apr 13, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Apr 10, 2026: Open-market sale of MLTX shares (Form 4, code S).
Other insiders filing for MoonLake Immunotherapeutics (MLTX)
- Reich Kristian, Chief Scientific Officer
- Bodenstedt Matthias, Chief Financial Officer
- BVF PARTNERS L P/IL, Director
- Phillips Andrew John, Director
- Loy Spike, Director
- Moukheibir Catherine, Director